Repurposing butenafine as an oral nanomedicine for visceral leishmaniasis

Bezerra-Souza, Adriana and Fernandez-Garcia, Raquel and Rodrigues, Gabriela F. and Bolas-Fernandez, Francisco and Laurenti, Marcia Dalastra and Passero, Luiz Felipe and Lalatsa, Aikaterini and Serrano, Dolores R. (2019) Repurposing butenafine as an oral nanomedicine for visceral leishmaniasis. Pharmaceutics, 11 (7). 353. ISSN 1999-4923 (https://doi.org/10.3390/pharmaceutics11070353)

[thumbnail of Bezerra-Souza-etal-Pharmaceutics-2019-Repurposing-butenafine-as-an-oral-nanomedicine]
Preview
 Text. Filename: Bezerra_Souza_etal_Pharmaceutics_2019_Repurposing_butenafine_as_an_oral_nanomedicine.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo
Download (1MB)| Preview

Abstract

Leishmaniasis is a neglected tropical disease affecting more than 12 million people worldwide, which in its visceral clinical form (VL) is characterised by the accumulation of parasites in the liver and spleen, and can lead to death if not treated. Available treatments are not well tolerated due to severe adverse effects, need for parenteral administration and patient hospitalisation, and long duration of expensive treatments. These treatment realities justify the search for new effective drugs, repurposing existing licensed drugs towards safer and non-invasive cost-effective medicines for VL. In this work, we provide proof of concept studies of butenafine and butenafine self-nanoemulsifying drug delivery systems (B-SNEDDS) against Leishmania infantum. Liquid B-SNEDDS were optimised using design of experiments, and then were spray-dried onto porous colloidal silica carriers to produce solid-B-SNEDDS with enhanced flow properties and drug stability. Optimal liquid B-SNEDDS consisted of Butenafine:Capryol 90:Peceol:Labrasol (3:49.5:24.2:23.3 w/w), which were then sprayed-dried with Aerosil 200 with a final 1:2 (Aerosil:liquid B-SNEDDS w/w) ratio. Spray-dried particles exhibited near-maximal drug loading, while maintaining excellent powder flow properties (angle of repose <10°) and sustained release in acidic gastrointestinal media. Solid-B-SNEDDS demonstrated greater selectivity index against promastigotes and L. infantum-infected amastigotes than butenafine alone. Developed oral solid nanomedicines enable the non-invasive and safe administration of butenafine as a cost-effective and readily scalable repurposed medicine for VL.

ORCID iDs

Bezerra-Souza, Adriana, Fernandez-Garcia, Raquel, Rodrigues, Gabriela F., Bolas-Fernandez, Francisco, Laurenti, Marcia Dalastra, Passero, Luiz Felipe, Lalatsa, Aikaterini ORCID logoORCID: https://orcid.org/0000-0003-4791-7468 and Serrano, Dolores R.;
CORE (COnnecting REpositories)